Nuclide

Publication counts reward volume. This index rewards presence in the evidence that changed practice: the trials, products, and technologies recorded in Nuclide that an institution or cooperative group is linked to. It is disclosed, simple, and only as complete as the corpus.

score = 3 × linked trials + 2 × linked products + linked technologies + linked targets, counting distinct Nuclide objects connected in either direction. Cooperative groups (SWOG, NRG, Alliance, BIG…) are included because they, not single hospitals, run most academic phase 3 trials. To move an institution up, document the trial it led and link it.
#InstitutionTrialsProductsTechnologiesTargetsScore
1-3 · Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Piflufolastat F-18 / Pylarify TruVu7013
22 · proPSMA, TheraP1 · Lutetium-177 vipivotide tetraxetan2010
32 · proPSMA, TheraP1 · Lutetium-177 vipivotide tetraxetan2010
41 · VISION2 · Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan209
5-2 · Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan509
6-2 · FAP-2286, Lutetium-177 vipivotide tetraxetan329
7-2 · Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan228
8-2 · Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan228
9-2 · Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan408
10
1 · STAMPEDE2 · Abiraterone acetate, Olaparib007
11-1 · Lutetium-177 dotatate417
12-1 · Gallium-68 gozetotide125
13--224
14-1 · Gallium-68 gozetotide114
15-1 · Lutetium-177 dotatate114
16--303
17--303
18--112
19-1 · Radioactive iodine002
20-1 · Technetium (99mTc) pexiretide002
21--202
22--112
23
-1 · Pembrolizumab002
24--202
25-1 · Pembrolizumab002
26-1 · Florastamin F-18002
27--202
28--202
29--101
30--101
31--101
32--101
33--011
34--101
35--101
36--101
37--101
38--101
39--101
40--101
41--101